Cite
Biochemical control of the combination of cyclooxygenase‐2 inhibitor and 125I‐brachytherapy for prostate cancer: Post hoc analysis of an open‐label controlled randomized trial.
MLA
Nakai, Yasushi, et al. “Biochemical Control of the Combination of Cyclooxygenase‐2 Inhibitor and 125I‐brachytherapy for Prostate Cancer: Post Hoc Analysis of an Open‐label Controlled Randomized Trial.” International Journal of Urology, vol. 27, no. 9, Sept. 2020, pp. 755–59. EBSCOhost, https://doi.org/10.1111/iju.14294.
APA
Nakai, Y., Tanaka, N., Asakawa, I., Anai, S., Miyake, M., Morizawa, Y., Hori, S., Owari, T., Fujii, T., Ohbayashi, C., Yamaki, K., Hasegawa, M., & Fujimoto, K. (2020). Biochemical control of the combination of cyclooxygenase‐2 inhibitor and 125I‐brachytherapy for prostate cancer: Post hoc analysis of an open‐label controlled randomized trial. International Journal of Urology, 27(9), 755–759. https://doi.org/10.1111/iju.14294
Chicago
Nakai, Yasushi, Nobumichi Tanaka, Isao Asakawa, Satoshi Anai, Makito Miyake, Yosuke Morizawa, Shunta Hori, et al. 2020. “Biochemical Control of the Combination of Cyclooxygenase‐2 Inhibitor and 125I‐brachytherapy for Prostate Cancer: Post Hoc Analysis of an Open‐label Controlled Randomized Trial.” International Journal of Urology 27 (9): 755–59. doi:10.1111/iju.14294.